The French biotechnology company Abivax announced tonight that it is terminating the clinical trial it was conducting for a candidate drug for Covid-19, due to the "ineffectiveness" of this preparation.
The drug, called ABX464, had been designated a "national priority" for research. In May 2020, the French regulators (ANSM) gave the green light to test its effectiveness.
The miR-AGE clinical trial involved 1.034 patients.
Source: RES-EAP